P-080Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). (2nd July 2019) - Samalin, E; Turpin, A; Khemissa, F; Zaanan, A; Benabdelghani, M; Senellart, H; Gilabert, M; Evesque, L; Dahan, L; Sefrioui, D; Bouché, O; De la Fouchardière, C; et al.